Journal
Breast Cancer: Targets and Therapy
Publication Date
4-29-2022
Volume
14
First Page
113
Last Page
123
Document Type
Open Access Publication
DOI
10.2147/BCTT.S293597
Rights and Permissions
Bagegni NA, Davis AA, Clifton KK, Ademuyiwa FO. Targeted Treatment for High-Risk Early-Stage Triple-Negative Breast Cancer: Spotlight on Pembrolizumab. Breast Cancer (Dove Med Press). 2022 Apr 29;14:113-123. doi.org/10.2147/BCTT.S293597 This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.
Recommended Citation
Bagegni, Nusayba A; Davis, Andrew A; Clifton, Katherine K; and Ademuyiwa, Foluso O, "Targeted treatment for high-risk early-stage triple-negative breast cancer: Spotlight on pembrolizumab." Breast Cancer: Targets and Therapy. 14, 113 - 123. (2022).
https://digitalcommons.wustl.edu/open_access_pubs/11971
